Edison
Our content

Our content

Edison Sparks - Morning News

Nicox – Focus on sight

Edison QuickView

Ultimovacs – Phase II data from 500+ patients over 2022/23

Healthcare Sector reports: T-cell therapies Part 1-17092017-Feature image

Chimeric Therapeutics – Scorpion venom CAR-T stalking GBM

Healthcare – Thoughts for the new year

ReNeuron Group – Continuing to gain clinical data in eye disease

Hepion Pharmaceuticals – First data on liver enzymes encouraging

Carmat – executive interview with Stéphane Piat

PRIMA_subretinal_3D

Pixium Vision – Pixium Vision to combine with Second Sight

InMed Pharmaceuticals – INM-755 Phase I complete, on to Phase II

Carmat – CE Mark achieved, launching in Q2

CASI Pharmaceuticals – executive interview

Oasmia Pharmaceutical – Clarity on pathway to US approval

Oasmia Pharmaceutical – executive interview

BioLargo – Firing on all cylinders

Immunicum – Potentially transformational merger

BerGenBio – Progressing towards key inflection points

Browse by content type